Abstract
Cardiovascular disease is the leading cause of mortality worldwide. Excessive oxidative stress and inflammation play an important role in the development and progression of cardiovascular disease. Molecular hydrogen, a small colorless and odorless molecule, is considered harmless in daily life when its concentration is below 4% at room temperature. Owing to the small size of the hydrogen molecule, it can easily penetrate the cell membrane and can be metabolized without residue. Molecular hydrogen can be administered through inhalation, the drinking of hydrogen-rich water, injection with hydrogen-rich-saline, and bathing of an organ in a preservative solution. The utilization of molecular hydrogen has shown many benefits and can be effective for a wide range of purposes, from prevention to the treatment of diseases. It has been demonstrated that molecular hydrogen exerts antioxidant, anti-inflammatory, and antiapoptotic effects, leading to cardioprotective benefits. Nevertheless, the exact intracellular mechanisms of its action are still unclear. In this review, evidence of the potential benefits of hydrogen molecules obtained from in vitro, in vivo, and clinical investigations are comprehensively summarized and discussed with a focus on the cardiovascular aspects. The potential mechanisms involved in the protective effects of molecular hydrogen are also presented. These findings suggest that molecular hydrogen could be used as a novel treatment in various cardiovascular pathologies, including ischemic–reperfusion injury, cardiac injury from radiation, atherosclerosis, chemotherapy-induced cardiotoxicity, and cardiac hypertrophy.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Molecular hydrogen is the lightest of all gas molecules. It is an odorless, colorless, tasteless, nonmetallic, and nontoxic gas at room temperature [1]. Hydrogen is not dangerous when its concentration is under 4% [1]. Owing to its small size, a hydrogen molecule has the ability to diffuse through the cell membrane and enter the cytosol. This characteristic of hydrogen makes it superior when it comes to the transport efficacy of most hydrophilic compounds, which are retained at membranes and cannot reach the cytosol; the majority of hydrophobic ones cannot penetrate biomembranes without specific carriers [2, 3]. Many antioxidants, including vitamins, can enter the cytoplasm but not the mitochondria [2]. It has been shown that hydrogen can be rapidly distributed into the cytosol and organelles, and it can enter the mitochondria and nucleus with excellent efficacy and lack of adverse effects [3].
There is growing evidence to demonstrate that hydrogen could be an effective treatment in various diseases due to its ability to reduce oxidative stress by selectively eliminating toxic reactive-oxygen species (ROS) and reactive nitrogen species (RNS) [4]. Hydrogen was found to increase the level of antioxidants in vitro studies, animal models, and clinical studies [5,6,7]. Furthermore, anti-inflammation and anticell death have also been reported as hydrogen properties [8]. In addition, the previous studies in both animal models and clinical trials demonstrated the potential benefits of hydrogen application in various pathological conditions, including postcardiac arrest syndrome [9] and cardiovascular diseases [10,11,12,13].
In this review, we comprehensively summarize the reports regarding the potential role of the therapeutic application of molecular hydrogen in the cardiovascular aspect and describe the potential mechanisms responsible for the benefits of hydrogen. These findings from both preclinical and clinical studies will encourage further investigations to warrant the application of hydrogen as a novel treatment in a clinical setting in the near future.
Effects of hydrogen treatment on cardiomyocytes: reports from in vitro studies
Hypoxia and reoxygenation (H/R) induced oxidative stress and inflammatory reaction is one of the main factors contributing to myocardial cell injury [6, 14, 15]. It has been demonstrated that hydrogen exerts antioxidative stress, antiapoptotic, and anti-inflammatory effects [16]. Following 4 h of hypoxia and 24 h of reoxygenation, a hydrogen-rich medium was shown to increase the survival of H9c2 cells by decreasing inflammatory cytokine release and apoptosis [15]. The protective effect of hydrogen against cell death, inflammatory process, or oxidative stress was shown to be through various pathways, including the PI3K/Akt signaling pathway and the activation of the Nrf2/HO-1 signaling, leading to increased OH-1 levels which is considered a potent antioxidant, and a decrease in 8-OHdG which is regarded as an indicator of oxidative stress (Figs. 1 and 2) [6, 14].
In cardiotrophin-I (CT-I)-induced hypertrophy neonatal rat cardiomyocytes, a hydrogen-rich medium effectively reduced cardiomyocyte hypertrophy via down-regulation of IL-6 and activation of the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) signaling pathway, leading to attenuation of adverse cardiac remodeling and the cell inflammatory response (Fig. 1) [17, 18]. These in vitro reports are comprehensively summarized in Table 1.
Effects of hydrogen treatment on the heart: reports from in vivo studies
Hydrogen treatment has been investigated in various in vivo models of cardiac pathology, including cardiac ischemia − reperfusion injury, myocardial infarction and chronic intermittent hypoxia, radiation, atherosclerosis, sepsis, cardiotoxicity from chemotherapy, and cardiac hypertrophy. The cardioprotective effects of hydrogen interventions are reported and summarized in Tables 2 and 3. The potential mechanisms of action of molecular hydrogen on selective antioxidants, anti-inflammation, and alleviating cell death are demonstrated in Figs. 1 and 2.
Effects of hydrogen treatment on cardiac ischemia − reperfusion injury models
Cardiac ischemia − reperfusion injury (I/R) could negatively affect outcomes in various clinical settings, including post myocardial infarction, cardiac transplantation, or cardiopulmonary bypass. Oxidative stress induced by I/R was found to cause direct cellular injury and apoptosis, leading to impaired cardiac function [15]. The oxidative stress involved in the cell death pathway is a consequence of the presence of reactive oxygen species (ROS), including the hydroxyl radical (•OH), superoxide anion (O2−), hydrogen peroxide (H2O2), in addition to reactive nitrogen species (RNS), including nitric oxide (NO), and peroxynitrite (ONOO−). Both ROS and RNS are known to trigger the production of inflammatory cytokines and proteins, including IL-1 \(\beta \), IL-6, and TNF-\(\alpha ,\) HMGB1, and ICAM-1 [19]. Hydrogen has been demonstrated to potentially protect against I/R injury through the mechanisms of reducing oxidative stress, inflammation, and cell death in various in vivo experimental settings.
In rats with cardiac I/R, hydrogen-rich saline (HRS) injected intraperitoneally was shown to improve cardiac function, reduce infarct size, and alleviate cardiac injury [5, 15, 20]. Studies using either injection into the myocardial tissue around the infarct zone or inhalation in rats showed consistently beneficial results [21,22,23]. In swine with cardiac I/R, inhalation of 2–4% hydrogen treatment resulted in the reduction of both myocardial infarct size and the incidence of ventricular fibrillation (VF)/ventricular tachycardia (VT) and improved cardiac function [24].
In the cardiopulmonary bypass model (CPB), rats treated with hydrogen-rich water (HRW) via intravenous injection showed an improvement in cardiac function and a reduction in cardiac injury [6]. Within the last few decades, studies using the heart transplant rat model have demonstrated that hydrogen given either orally or by inhalation resulted in reduced infarct size and cardiac injury and enhanced the survival of cardiac grafts [11, 25]. Overall, evidence from these in vivo reports indicated that hydrogen treatment effectively reduced infarct size and myocardial injury, leading to improved cardiac function.
The precise mechanisms involved during hydrogen treatment with regard to improving cardiac function and alleviating myocardial infarction and cardiac injury are still unclear, but the reduction in oxidative stress and inflammation could be key [5, 15, 20,21,22]. Hydrogen has been shown to effectively decrease oxidative stress indicators, including MDA, 8-OHdG, MPO, and ROS in rats with I/R, CBP, and in transplantation models [5, 6, 15, 20,21,22,23] as well as decreasing endoplasmic reticulum (ER) stress including TRAF2, and GRP78 in an I/R rat model [5, 6, 15, 20,21,22,23]. An increase in antioxidants, including SOD, was also demonstrated in rat models of I/R injury and CBP [5, 6, 15, 20,21,22,23]. Hydrogen treatment also led to a reduction in inflammation via increased autophagy, PINK/Parkin-mediated mitophagy [6, 11, 15, 20, 21, 26], and antiapoptosis [5, 6, 11, 15, 21, 23]. All of these mechanisms could lead to improved cardiac function in these models.
Effects of hydrogen treatment in myocardial infarction (MI) and chronic intermittent hypoxia (CIH) models
Myocardial infarction (MI), widely accepted as one of the major causes of death, can induce myocardial necrosis and interstitial fibrosis resulting in heart failure, and increasing the mortality rate [27]. In rats with MI, hydrogen treatment via ingestion, inhalation, or intraperitoneal injection was shown to improve cardiac function and attenuate myocardial pathological changes by reducing the infarct size and apoptosis [28,29,30]. In rats with CIH, hydrogen therapy has been shown to reduce cardiac dysfunction by reducing oxidative stress. In addition, hydrogen attenuated ER stress-induced apoptosis via PERK-eIF2 \(\alpha \)-ATF4, IRE 1-XBP1, and ATF6 pathways [31]. Moreover, a combination of HRS with exercise was shown to promote the repair of both the mitochondria and DNA in a rat MI model, which could be involved in the cardioprotective mechanism of hydrogen treatment [29].
Effects of hydrogen treatment in a radiation model
Radiation can cause myocardial damage as a consequence of radiation-induced myocardial fibrosis, leading to the chronic impairment of cardiac function [32]. In a radiated rat model, it has been demonstrated that an intake of oral hydrogen prior to radiation increased survival rate by increasing the level of antioxidants, reducing oxidative stress, and preventing DNA damage [33]. However, the effect of hydrogen treatment on cardiac function in these conditions is unknown.
Effects of hydrogen treatment in an atherosclerosis model
Atherosclerosis is a multifactorial process which is related to cardiovascular disease. It represents a state of inflammation and oxidative stress characterized by the accumulation of macrophages and oxidized products of lipoproteins in the affected blood vessels [34]. Interestingly, the consumption of HRS for 6 months effectively decreased oxidative stress and had the potential to decrease atherosclerotic lesions in the aorta [35].
Effects of hydrogen treatment on the heart in a sepsis model
Sepsis is systemic inflammation in response to an infection associated with the cardiovascular system. Cardiac myocytes are involved due to the oxygen consumption of the cell being compromised. Correspondingly, mitochondrial dysfunction occurs, leading to cellular energy depletion [36]. A recent study showed that hydrogen gas treatment reduced mitochondrial dysfunction by up-regulating the protein expression of mitofusin-2 (Mfn2), peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α), and protein heme-oxygenase-1 (HO-1) [37]. However, the effect of hydrogen treatment on cardiac function in these conditions is unknown.
Effects of hydrogen treatment in a chemotherapy-induced cardiotoxicity model
Doxorubicin is an anthracycline anticancer drug that can cause cardiotoxicity, a condition known as doxorubicin-induced cardiomyopathy, via oxidative stress, apoptosis, and intracellular calcium dysregulation [38]. The use of HRS via intraperitoneal injection in rats treated with doxorubicin has been shown to improve survival rate and reduce cardiac dysfunction by attenuating oxidative stress, inflammation, and apoptosis [12].
Effects of hydrogen treatment in a cardiac hypertrophy model
Cardiac hypertrophy, consisting of interstitial and perivascular fibrosis, can lead to heart failure, which results in increased mortality [39]. Hypertension is the major factor associated with left ventricular hypertrophy [40]. Studies into cardiac hypertrophy in rat models reported that hydrogen therapy using HRS via IP resulted in a reduction in heart and atrial weight [13, 17, 18, 41]. Hydrogen also decreased the incidence of atrial fibrillation (AF), atrial fibrosis, apoptosis, and inflammation through the downregulation of the JAK-STAT signaling [17, 18]. In another rat model with cardiac hypertrophy, the benefit of hydrogen therapy was shown via a reduction in oxidative stress, the inflammatory process, and angiotensin II, and the preservation of mitochondrial function in the left ventricle [13, 41]. These benefits could be due to the inhibition of the TGF-β/Smad signaling pathway, leading to reduced cardiac hypertrophy [41].
Effects of hydrogen treatment on the heart: reports from ex vivo studies
Heart transplant is one of the causes of I/R injury. A period of cold ischemia due to tissue matching and transportation is inevitable after retrieval of the heart. The organ preservation solutions have been found to only partially alleviate ischemia injury during storage [42]. In isolated hearts mounted on the Langendorff apparatus for aerobic perfusion, it has been shown that preservation in H2-rich with Histidine − Tryptophan − Ketoglutarate (HTK) significantly improved cardiac function in a hydrogen concentration-dependent manner as well as attenuated the microscopic pathology of the myocardium [43]. The protective mechanism of hydrogen was via inhibition of cold ischemia-induced up-regulation of oxidative stress, inflammation mediators, and apoptosis (Figs. 1 and 2) [43]. In a study using syngeneic heart grafts from elderly donors or allografts from adult donors and exposing them to prolonged cold preservation, the cardiac grafts immersed in the cold-water bath with hydrogen showed ameliorated myocardial injury [26]. The grafts exhibited inflammatory responses, including neutrophil infiltration, and increases in pro-inflammatory cytokines and chemokines, whereas hydrogen induced lower levels of mitochondrial damage and higher adenosine triphosphate content [26]. In a recent study using an isolated heart model with I/R injury, perfusion with HRW resulted in a decrease in apoptosis by up-regulating the JAK-STAT and PI3K-AKT signaling pathways (Fig. 2) [44]. All of these ex vivo reports are comprehensively summarized in Table 4.
Effects of hydrogen treatment on the heart: Evidence from clinical studies
Because molecular hydrogen has various potential therapeutic effects, it has been investigated in various pathophysiological conditions in clinical settings. It has been suggested that hydrogen has an effective therapeutic approach in the heart for improving outcomes associated with I/R injury. A randomized single-center prospective, open-label, blinded study to investigate the feasibility and effects of hydrogen on the infarct size and adverse left ventricular (LV) remodeling in patients with ST-elevated MI (STEMI) was conducted after primary percutaneous coronary intervention (PCI) [10]. This first clinical trial showed that hydrogen inhalation during PCI is genuinely feasible, promotes LV reverse remodeling 6 months after STEMI, and improves cardiac function [10]. Another recent clinical trial enrolled five comatose postcardiac arrest patients [45]. The study demonstrated that oxidative stress was reduced while the cytokine levels were unchanged in cardiogenic patients. However, the oxidative stress was unchanged in septic patients, but the cytokine levels were diminished. Nevertheless, the effect of inhaled hydrogen on oxidative stress and cytokines remained inconclusive due to potential methodological weaknesses [45].
Various in vivo and in vitro studies demonstrate hydrogen’s ability to reduce inflammation and antiapoptotic properties. A randomized, double-blind, controlled trial showed hydrogen increases antioxidant capacity, thereby reducing inflammatory responses and apoptosis in healthy adults [46].
Because metabolic syndrome remains a serious concern, those patients are at increased risk of developing cardiovascular disease. Hydrogen decreases serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and apo-B levels. Moreover, hydrogen therapy was shown to improve high-density lipoprotein (HDL) function and reduced oxidative stress in patients with metabolic syndrome [47, 48]. All of these clinical studies are comprehensively summarized in Table 5. The potential mechanism of action of molecular hydrogen on selective antioxidants, anti-inflammation, and alleviating cell death are demonstrated in Figs. 1 and 2.
Conclusion and future perspectives
Molecular hydrogen has versatile therapeutic effects due to its small size. It can penetrate the cell membrane and affect metabolism in the body. Molecular hydrogen can be administered via several methods including inhalation, drinking of hydrogen-rich water, injection with hydrogen-rich-saline, and bathing of an organ in a preservation solution. Cumulative evidence from in vivo, in vitro, ex vivo, and clinical studies demonstrated the possible mechanisms underlying the potential benefits of molecular hydrogen, including those increasing antioxidants and decreasing oxidative stress, cell death, metabolism, and inflammation.
For future research, searching for the mechanism of molecular hydrogen to reduce ventricular dilation, decrease wall stress, and reverse adverse cardiac remodeling should be thoroughly investigated. In addition, future clinical studies investigating oxidative stress and inflammatory pathways may provide information to improve the current treatment of various inflammatory diseases, including Kawasaki disease, COVID-19 infection, a multisystem inflammatory syndrome in children or adult (MIS-C or A). Although various in vitro and in vivo models have demonstrated the beneficial effects of molecular hydrogen treatment on the heart, clinical investigations are still limited. Future large-scale randomized control trials are needed to determine the crucial clinical impact of using hydrogen as a therapy, and to verify the efficacy and safety of clinical interventions with molecular hydrogen to warrant its use and to improve medical treatment in this field.
Availability of data and material
Enquiries about data availability should be directed to the authors.
References
Dixon BJ, Tang J, Zhang JH (2013) The evolution of molecular hydrogen: a noteworthy potential therapy with clinical significance. Med Gas Res 3:10
Szeto HH (2006) Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J 8:E521–E531
Ohsawa I, Ishikawa M, Takahashi K, Watanabe M, Nishimaki K, Yamagata K et al (2007) Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med 13:688–694
Ohta S (2012) Molecular hydrogen is a novel antioxidant to efficiently reduce oxidative stress with potential for the improvement of mitochondrial diseases. Biochim Biophys Acta 1820:586–594
Sun Q, Kang Z, Cai J, Liu W, Liu Y, Zhang JH et al (2009) Hydrogen-rich saline protects myocardium against ischemia/reperfusion injury in rats. Exp Biol Med (Maywood) 234:1212–1219
Song D, Liu X, Diao Y, Sun Y, Gao G, Zhang T et al (2018) Hydrogen-rich solution against myocardial injury and aquaporin expression via the PI3K/Akt signaling pathway during cardiopulmonary bypass in rats. Mol Med Rep 18:1925–1938
LeBaron TW, Kura B, Kalocayova B, Tribulova N, Slezak J (2019) A new approach for the prevention and treatment of cardiovascular disorders. Molecular hydrogen significantly reduces the effects of oxidative stress. Molecules 24:2076
Ohta S (2014) Molecular hydrogen as a preventive and therapeutic medical gas: initiation, development and potential of hydrogen medicine. Pharmacol Ther 144:1–11
Tamura T, Hayashida K, Sano M, Onuki S, Suzuki M (2017) Efficacy of inhaled HYdrogen on neurological outcome following BRain Ischemia During post-cardiac arrest care (HYBRID II trial): study protocol for a randomized controlled trial. Trials 18:488
Katsumata Y, Sano F, Abe T, Tamura T, Fujisawa T, Shiraishi Y et al (2017) The effects of hydrogen gas inhalation on adverse left ventricular remodeling after percutaneous coronary Intervention for ST-elevated myocardial infarction—first pilot study in humans. Circ J 81:940–947
Nakao A, Kaczorowski DJ, Wang Y, Cardinal JS, Buchholz BM, Sugimoto R et al (2010) Amelioration of rat cardiac cold ischemia/reperfusion injury with inhaled hydrogen or carbon monoxide, or both. J Heart Lung Transplant 29:544–553
Gao Y, Yang H, Fan Y, Li L, Fang J, Yang W (2016) Hydrogen-rich saline attenuates cardiac and hepatic injury in doxorubicin rat model by inhibiting inflammation and apoptosis. Mediators Inflamm 2016:1320365
Yu YS, Zheng H (2012) Chronic hydrogen-rich saline treatment reduces oxidative stress and attenuates left ventricular hypertrophy in spontaneous hypertensive rats. Mol Cell Biochem 365:233–242
Xie Q, Li XX, Zhang P, Li JC, Cheng Y, Feng YL et al (2014) Hydrogen gas protects against serum and glucose deprivation-induced myocardial injury in H9c2 cells through activation of the NF-E2-related factor 2/heme oxygenase 1 signaling pathway. Mol Med Rep 10:1143–1149
Yao L, Chen H, Wu Q, Xie K (2019) Hydrogen-rich saline alleviates inflammation and apoptosis in myocardial I/R injury via PINK-mediated autophagy. Int J Mol Med 44:1048–1062
Li J, Hong Z, Liu H, Zhou J, Cui L, Yuan S et al (2016) Hydrogen-rich saline promotes the recovery of renal function after ischemia/reperfusion injury in rats via anti-apoptosis and anti-inflammation. Front Pharmacol 7:106
Wang C, Pan Z (2020) Hydrogen-rich saline mitigates pressure overload-induced cardiac hypertrophy and atrial fibrillation in rats via the JAK-STAT signalling pathway. J Int Med Res 48:300060520936415
Fan Z, Gao Y, Huang Z, Xue F, Wu S, Yang J et al (2018) Protective effect of hydrogen-rich saline on pressure overload-induced cardiac hypertrophyin rats: possible role of JAK-STAT signaling. BMC Cardiovasc Disord 18:32
Buckley LF, Libby P (2019) Inhibiting NLRP3 inflammasome activity in acute myocardial infarction: a review of pharmacologic agents and clinical outcomes. J Cardiovasc Pharmacol 74:297–305
Zhang Y, Sun Q, He B, Xiao J, Wang Z, Sun X (2011) Anti-inflammatory effect of hydrogen-rich saline in a rat model of regional myocardial ischemia and reperfusion. Int J Cardiol 148:91–95
Zhang G, Gao S, Li X, Zhang L, Tan H, Xu L et al (2015) Pharmacological postconditioning with lactic acid and hydrogen rich saline alleviates myocardial reperfusion injury in rats. Sci Rep 5:9858
Hayashida K, Sano M, Ohsawa I, Shinmura K, Tamaki K, Kimura K et al (2008) Inhalation of hydrogen gas reduces infarct size in the rat model of myocardial ischemia−reperfusion injury. Biochem Biophys Res Commun 373:30–35
Gao Y, Yang H, Chi J, Xu Q, Zhao L, Yang W et al (2017) Hydrogen gas attenuates myocardial ischemia reperfusion injury independent of postconditioning in rats by attenuating endoplasmic reticulum stress-induced autophagy. Cell Physiol Biochem 43:1503–1514
Sakai K, Cho S, Shibata I, Yoshitomi O, Maekawa T, Sumikawa K (2012) Inhalation of hydrogen gas protects against myocardial stunning and infarction in swine. Scand Cardiovasc J 46:183–189
Noda K, Tanaka Y, Shigemura N, Kawamura T, Wang Y, Masutani K et al (2012) Hydrogen-supplemented drinking water protects cardiac allografts from inflammation-associated deterioration. Transpl Int 25:1213–1222
Noda K, Shigemura N, Tanaka Y, Kawamura T, Hyun Lim S, Kokubo K et al (2013) A novel method of preserving cardiac grafts using a hydrogen-rich water bath. J Heart Lung Transplant 32:241–250
Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T et al (2007) Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 370:1483–1493
Jing L, Wang Y, Zhao XM, Zhao B, Han JJ, Qin SC et al (2015) Cardioprotective effect of hydrogen-rich saline on isoproterenol-induced myocardial infarction in rats. Heart Lung Circ 24:602–610
Feng R, Cai M, Wang X, Zhang J, Tian Z (2019) Early aerobic exercise combined with hydrogen-rich saline as preconditioning protects myocardial injury induced by acute myocardial infarction in rats. Appl Biochem Biotechnol 187:663–676
Yang H, Liu S, Du H, Hong Z, Lv Y, Nie C et al (2021) Hydrogen attenuates myocardial injury in rats by regulating oxidative stress and NLRP3 inflammasome mediated pyroptosis. Int J Med Sci 18:3318–3325
Zhao YS, An JR, Yang S, Guan P, Yu FY, Li W et al (2019) Hydrogen and oxygen mixture to improve cardiac dysfunction and myocardial pathological changes induced by intermittent hypoxia in rats. Oxid Med Cell Longev 2019:7415212
Wang B, Wang H, Zhang M, Ji R, Wei J, Xin Y et al (2020) Radiation-induced myocardial fibrosis: mechanisms underlying its pathogenesis and therapeutic strategies. J Cell Mol Med 24:7717–7729
Qian L, Cao F, Cui J, Wang Y, Huang Y, Chuai Y et al (2010) The potential cardioprotective effects of hydrogen in irradiated mice. J Radiat Res 51:741–747
Papaharalambus CA, Griendling KK (2007) Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med 17:48–54
Ohsawa I, Nishimaki K, Yamagata K, Ishikawa M, Ohta S (2008) Consumption of hydrogen water prevents atherosclerosis in apolipoprotein E knockout mice. Biochem Biophys Res Commun 377:1195–1198
Landesberg G, Levin PD, Gilon D, Goodman S, Georgieva M, Weissman C et al (2015) Myocardial dysfunction in severe sepsis and septic shock: no correlation with inflammatory cytokines in real-life clinical setting. Chest 148:93–102
Zhang Y, Dong A, Xie K, Yu Y (2020) Protective effects of hydrogen on myocardial mitochondrial functions in septic mice. Biomed Res Int 2020:1568209
Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL (2012) Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52:1213–1225
Ku HC, Lee SY, Wu YA, Yang KC, Su MJ (2016) A model of cardiac remodeling through constriction of the abdominal aorta in rats. J Vis Exp. https://doi.org/10.3791/54818
Paolisso G, Galzerano D, Gambardella A, Varricchio G, Saccomanno F, D’Amore A et al (1995) Left ventricular hypertrophy is associated with a stronger impairment of non-oxidative glucose metabolism in hypertensive patients. Eur J Clin Invest 25:529–533
Liu L, Shi Q, Liu X, Li Y, Li X (2021) Attenuation of myocardial fibrosis using molecular hydrogen by inhibiting the TGF-β signaling pathway in spontaneous hypertensive rats. Am J Hypertens. https://doi.org/10.1093/ajh/hpab159
Salahudeen AK (2004) Cold ischemic injury of transplanted kidneys: new insights from experimental studies. Am J Physiol Renal Physiol 287:F181–F187
Tan M, Sun X, Guo L, Su C, Xu Z (2013) Hydrogen as additive of HTK solution fortifies myocardial preservation in grafts with prolonged cold ischemia. Int J Cardiol 167:383–390
Li L, Liu T, Li X, Liu X, Liu L, Li S et al (2019) Protein chip and bioinformatic analyses of differentially expressed proteins involved in the effect of hydrogen-rich water on myocardial ischemia−reperfusion injury. Int J Med Sci 16:1254–1259
Tamura T, Suzuki M, Hayashida K, Kobayashi Y, Yoshizawa J, Shibusawa T et al (2020) Hydrogen gas inhalation alleviates oxidative stress in patients with post-cardiac arrest syndrome. J Clin Biochem Nutr 67:214–221
Sim M, Kim CS, Shon WJ, Lee YK, Choi EY, Shin DM (2020) Hydrogen-rich water reduces inflammatory responses and prevents apoptosis of peripheral blood cells in healthy adults: a randomized, double-blind, controlled trial. Sci Rep 10:12130
Nakao A, Toyoda Y, Sharma P, Evans M, Guthrie N (2010) Effectiveness of hydrogen rich water on antioxidant status of subjects with potential metabolic syndrome—an open label pilot study. J Clin Biochem Nutr 46:140–149
Song G, Li M, Sang H, Zhang L, Li X, Yao S et al (2013) Hydrogen-rich water decreases serum LDL-cholesterol levels and improves HDL function in patients with potential metabolic syndrome. J Lipid Res 54:1884–1893
Acknowledgements
This work was supported by the NSTDA Research Chair Grant from the National Science and Technology Development Agency Thailand (NC), the Distinguished Research Professor Grant from the National Research Council of Thailand (N42A660301 to SCC), and the Chiang Mai University Center of Excellence Award (NC).
Funding
This work was supported by National Science and Technology Development Agency (Research Chair Grant). National Research Council of Thailand (Distinguished Research Professor Grant). Chiang Mai University (Center of Excellence Award).
Author information
Authors and Affiliations
Contributions
KS, SCC and NC: conceptualization. KS: wrote the original manuscript. RS, SCC and NC: edited the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Saengsin, K., Sittiwangkul, R., Chattipakorn, S.C. et al. Hydrogen therapy as a potential therapeutic intervention in heart disease: from the past evidence to future application. Cell. Mol. Life Sci. 80, 174 (2023). https://doi.org/10.1007/s00018-023-04818-4
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00018-023-04818-4